Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 4/2013

01-08-2013 | IMMUNOTHERAPY (L COX, SECTION EDITOR)

Accelerated Immunotherapy Schedules

Author: Christopher W. Calabria

Published in: Current Allergy and Asthma Reports | Issue 4/2013

Login to get access

Abstract

Rush and cluster immunotherapy schedules are accelerated immunotherapy build-up schedules. A cluster immunotherapy schedule involves the patient receiving several allergen injections (generally 2–4) sequentially in a single day of treatment on nonconsecutive days. The maintenance dose is generally reached in 4–8 weeks. In rush immunotherapy protocols, higher doses are administered at 15- to 60-min intervals over a 1- to 3-day period until the maintenance dose is achieved. This review will serve as an update for accelerated immunotherapy schedules. The review will include recent investigations demonstrating the safety of cluster schedules in atopic dermatitis, pediatric patients, and inhalant allergen mixtures and an accelerated protocol utilizing an infusion pump for allergen delivery. There has also been further elucidation on the immunological changes which occur during accelerated immunotherapy. Finally, new studies analyzing systemic reaction risk factors are discussed.
Literature
1.
• Kim M-E, Kim J-E, Sung J-M, et al. Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis. J Korean Med Sci. 2011;26:1159–64. Study examining cluster in atopic dermatitis patients.PubMedCrossRef
2.
Hernandez N, Ibero M, Ridao M, et al. Safety of specific immunotherapy using a depigmented and polymerized extract of Dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol (Madr). 2011;39(5):267–70.CrossRef
3.
Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251–60.PubMedCrossRef
4.
• Copenhaver C, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol. 2011;107:441–7. Recent American study using the cluster schedule recommended in the practice parameter and analyzing systemic reaction risk factors to cluster immunotherapy.PubMedCrossRef
5.
Pfaar O, Mosges R, Hormann K, Klimek L. Safety aspects of cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2010;267:245–50.PubMedCrossRef
6.
• Davis LS, Bhutani S, Barnett SR, Khan D. Early gene expression changes with rush immunotherapy. Clin Mol Allergy. 2011;9:12. This study examined whole genome expression profiling to identify changes in mRNA expression of peripheral blood mononuclear cells from allergic patients undergoing RIT.PubMedCrossRef
7.
Lou W, Wang C, Wang Y, et al. Enhancement of the frequency and function of IL-10-secreting type 1 T regulatory cells after 1 year of cluster allergen-specific immunotherapy. Int Arch Allergy Immunol. 2012;159:391–8.PubMedCrossRef
8.
Lou W, Wang C, Wang Y, et al. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type 1 T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol. 2012;23:140–9.PubMedCrossRef
9.
• Sastre J, Vallejo L, Hernandez E, et al. Rush allergen subcutaneous immunotherapy administered with infusion pump. Ann Allergy Asthma Immunol. 2011;107:459–60. This study utilized a portable battery-operated infusion pump to deliver allergen subcutaneously to 81 allergic rhinitis subjects and analyzed systemic reaction rates. PubMedCrossRef
10.
Justicia JL, Barasona MJ, Serrano P, et al. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol. 2006;17(6):386–92.
11.
• Vegh AB, George KC, Lotfi-Emran S, et al. Total tryptase levels indicated risk for systemic reactions to rush immunotherapy and mast cell activation. Ann Allergy Asthma Immunol. 2011;106:342–3. This recent study found higher baseline tryptase levels in systemic reaction patients compared to non-SR patients undergoing RIT to an inhalant mixture.PubMedCrossRef
12.
Nanda A, O’Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004;114:1339–44.PubMedCrossRef
13.
Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116:109–18.PubMedCrossRef
14.
Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–5.PubMedCrossRef
15.
Serrano P, Justicia JL, Sanchez C, et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol. 2009;102:247–52.PubMedCrossRef
16.
Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol. 2009;148:161–9.PubMedCrossRef
17.
Martinez-Canavate A, Eseverri JL, Rodenas R, et al. Evaluation of paediatric tolerance to an extract of Alternaria alternate under two treatment regimes. A multicentre study. Allergol Immunopathol. 2005;33(3):138–41.CrossRef
18.
Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97:1207–13.PubMedCrossRef
19.
Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II: side-effects. Allergy. 2000;55:327–35.
20.
Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30:1423–9.PubMedCrossRef
21.
Subiza J, Feliu A, Subiza JL, et al. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy. 2008;38(6):987–94.PubMedCrossRef
22.
Pfaar O, van Twuijver E, Hecker H, et al. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Int Arch Allergy Immunol. 2012;160(4):420–4.PubMedCrossRef
23.
Colas C, Monzon S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol. 2006;117:810–6.PubMedCrossRef
24.
Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97:126–38.PubMedCrossRef
25.
Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992;90:567–78.PubMedCrossRef
26.
Parmiani S, Fernandez T, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol. 2002;30(5):283–91.CrossRef
27.
Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107:87–93.PubMedCrossRef
28.
Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol. 2006;38(1):31–4.PubMed
29.
Harvey SM. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol. 2004;92:414–9.PubMedCrossRef
30.
Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy Asthma Immunol. 1994;73:409–18.
31.
Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy. 1994;73:423–8.PubMed
32.
Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006;16:79–85.PubMed
33.
Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol. 2003;91:405–10.PubMedCrossRef
34.
Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004;92:409–13.PubMedCrossRef
35.
Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol. 2002;109:556–62.PubMedCrossRef
36.
Dietrich JJ, Moore LM, Nguyen S, Hagan LL, Tankersley MS. Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication. Ann Allergy Asthma Immunol. 2009;103:535–6.PubMedCrossRef
37.
Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989;83:797–802.PubMedCrossRef
38.
Heijaioui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol. 1992;89:925–33.CrossRef
39.
Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy Asthma Immunol. 1989;63:127–35.
40.
Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy Asthma Immunol. 1986;56:456–9.
41.
Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, I: rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80:591–8.PubMedCrossRef
42.
Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol. 2001;86:337–42.PubMedCrossRef
43.
Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–40.PubMedCrossRef
44.
Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species, II: efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991;88:43–53.PubMedCrossRef
45.
Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy. 1985;15:179–93.PubMedCrossRef
46.
Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, III: efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 1989;84:546–56.PubMedCrossRef
47.
Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996;51:489–500.PubMed
48.
Pfaar O, Urry Z, Robinson DS, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–9.PubMedCrossRef
49.
Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85:460–72.PubMedCrossRef
50.
Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts, V: effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87:955–64.PubMedCrossRef
51.
Hedlin G, Braff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts, II: in vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol. 1986;77:488–96.PubMedCrossRef
52.
Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995;96:879–85.PubMedCrossRef
53.
Lilja G, Sundin B, Graff-Lonnevig V, et al. Immunotherapy with cat- and dog-dander extracts, IV: effects of 2 years of treatment. J Allergy Clin Immunol. 1989;83:37–44.PubMedCrossRef
54.
Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy Asthma Immunol. 1992;68:493–8.
55.
Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol. 1996;76:175–80.PubMedCrossRef
56.
Brehler R, Klimek L, Pfaar O, et al. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc. 2010;31(3):e31–8.PubMedCrossRef
57.
Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol. 2002;110:928–33.
58.
Patella V, Florio G, Giuliano A et al. Hymenoptera Venom Immunotherapy: Tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. Journal of Allergy 2012; article ID 192192, 8 pages.
59.
Riccio AM, Saverino D, Pesce G, et al. Effects of different up-dosing regimens for Hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS One. 2012;7(6):e37980.PubMedCrossRef
60.
Celesnik N, Vesel T, Rijavec M, et al. Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response. Allergy. 2012;67(12):1594–600.PubMed
61.
Patella V, Incorvaia C, Ricciardi L, et al. The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy. J Biol Regul Homeost Agents. 2011;25(3):465–8.PubMed
62.
Cichocka-Jaroxz E, Dorynska A, Pietrzyk JJ, Spiewak R. Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children. Immunotherapy. 2011;3(8):1013–7.CrossRef
63.
Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000;55:484–8.PubMedCrossRef
64.
Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997;100:458–63.PubMedCrossRef
65.
Berchtold E, Maibach R, Muller U. Reduction of side effect from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy. 1992;22:59–65.PubMedCrossRef
66.
Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81–6.PubMedCrossRef
67.
Muller U, Jutel M, Reimers A, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol. 2008;122:1001–7.PubMedCrossRef
68.
Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose–response study with standardized cat extract. J Allergy Clin Immunol. 2003;111:155–61.PubMedCrossRef
69.
Wohrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol. 2007;144:137–42.PubMedCrossRef
70.
Heijaioui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85:473–9.CrossRef
71.
• Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383–9. A prospective study which examined the effect of 16 weeks of treatment with omalizumab or placebo on the incidence of SR during cluster immunotherapy in 248 asthmatic subjects.PubMedCrossRef
72.
Calabria CW, Cox L. Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin N Am. 2011;31:251–63.CrossRef
Metadata
Title
Accelerated Immunotherapy Schedules
Author
Christopher W. Calabria
Publication date
01-08-2013
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 4/2013
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-013-0356-x

Other articles of this Issue 4/2013

Current Allergy and Asthma Reports 4/2013 Go to the issue

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Celiac Disease and Autoimmunity: Review and Controversies

IMMUNOTHERAPY (L COX, SECTION EDITOR)

Recombinant Allergen Immunotherapy: Clinical Evidence of Efficacy—A Review

IMMUNOTHERAPY (L COX, SECTION EDITOR)

Immunotherapy Preparation Guidelines, Rules, and Regulation

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Update on the Treatment of Juvenile Idiopathic Arthritis

IMMUNOTHERAPY (L COX, SECTION EDITOR)

Allergen Immunotherapy Extract Treatment Set Preparation: Making a Safer and Higher Quality Product for Patients

AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Autoimmunity in Immunodeficiency